REVIEW ARTICLE
Anorectal melanoma
Suzanne Fastner BS,
Tina J. Hieken MD,
Robert R. McWilliams MD,
John Hyngstrom MD,
Suzanne Fastner BS
Huntsman Cancer Institute, Salt Lake City, Utah, USA
Search for more papers by this authorTina J. Hieken MD
Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorRobert R. McWilliams MD
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorCorresponding Author
John Hyngstrom MD
Huntsman Cancer Institute, Salt Lake City, Utah, USA
Department of Surgery, Division of Surgical Oncology, University of Utah, Salt Lake City, Utah, USA
Correspondence John Hyngstrom, MD, Huntsman Cancer Hospital, University of Utah Health, 1950 Cir of Hope Dr, Salt Lake City, UT 84132, USA.
Email: [email protected]
Search for more papers by this authorSuzanne Fastner BS,
Tina J. Hieken MD,
Robert R. McWilliams MD,
John Hyngstrom MD,
Suzanne Fastner BS
Huntsman Cancer Institute, Salt Lake City, Utah, USA
Search for more papers by this authorTina J. Hieken MD
Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorRobert R. McWilliams MD
Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA
Search for more papers by this authorCorresponding Author
John Hyngstrom MD
Huntsman Cancer Institute, Salt Lake City, Utah, USA
Department of Surgery, Division of Surgical Oncology, University of Utah, Salt Lake City, Utah, USA
Correspondence John Hyngstrom, MD, Huntsman Cancer Hospital, University of Utah Health, 1950 Cir of Hope Dr, Salt Lake City, UT 84132, USA.
Email: [email protected]
Search for more papers by this authorFirst published: 03 July 2023
Abstract
Anorectal melanoma is an aggressive mucosal melanoma subtype with a poor prognosis. Although recent advancements have been seen for cutaneous melanoma, the optimal treatment paradigm for management of anorectal melanoma is evolving. In this review, we highlight differences in the pathogenesis of mucosal versus cutaneous melanoma, new concepts of staging for mucosal melanoma, updates to surgical management of anorectal melanoma, and current data for adjuvant radiation and systemic therapy in this unique patient population.
Open Research
DATA AVAILABILITY STATEMENT
Data sharing is not applicable to this article as no primary data were created or analyzed in this study.
REFERENCES
- 1 National Cancer Institute. SEER Cancer Stat Facts: Melanoma of the Skin. National Cancer Institute. https://seer.cancer.gov/statfacts/html/melan.html
- 2Ng YYR, Tan GHC, Quek RHH, Farid MBHR, Soo KC, Teo MCC. Clinical patterns and management of primary mucosal melanoma: a single centre experience. ANZ J Surg. 2018; 88(11): 1145-1150.
- 3Chen H, Cai Y, Liu Y, et al. Incidence, surgical treatment, and prognosis of anorectal melanoma from 1973 to 2011 a population-based SEER analysis. Medicine. 2016; 95(7):e2770.
- 4Kahl AR, Gao X, Chioreso C, et al. Presentation, management, and prognosis of primary gastrointestinal melanoma: a population-based study. J Surg Res. 2021; 260: 46-55.
- 5Lei X, Qingqing L, Weijie Y, et al. Effect of surgical treatment for anorectal melanoma: a propensity score-matched analysis of the surveillance, epidemiology, and end results programme data. BMJ Open. 2022; 12(4):e053339.
- 6Jutten E, Kruijff S, Francken AB, et al. Surgical treatment of anorectal melanoma: a systematic review and meta-analysis. BJS Open. 2021; 5(6):zrab107. doi:10.1093/bjsopen/zrab107
- 7Bello DM, Smyth E, Perez D, et al. Anal versus rectal melanoma: does site of origin predict outcome? Dis Colon Rectum. 2013; 56(2): 150-157.
- 8Ogata D, Tsutsui K, Namikawa K, et al. Treatment outcomes and prognostic factors in 47 patients with primary anorectal malignant melanoma in the immune therapy era. J Cancer Res Clin Oncol. 2023; 149(2): 749-755.
- 9Furney SJ, Turajlic S, Stamp G, et al. Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma. J Pathol. 2013; 230(3): 261-269.
- 10Paolino G, Didona D, Macrì G, Calvieri S, Mercuri SR. Anorectal Melanoma. Codon Publications; 2018: 83-98.
- 11Nassar KW, Tan AC. The mutational landscape of mucosal melanoma. Sem Cancer Biol. 2020; 61: 139-148.
- 12Yang HM, Hsiao SJ, Schaeffer DF, et al. Identification of recurrent mutational events in anorectal melanoma. Mod Pathol. 2017; 30(2): 286-296.
- 13Sarac E, Amaral T, Keim U, et al. Prognostic factors in 161 patients with mucosal melanoma: a study of German Central Malignant Melanoma Registry. J Eur Acad Dermatol Venereol. 2020; 34(9): 2021-2025.
- 14Carbó-Bagué A, Rubió-Casadevall J, Puigdemont M, et al. Epidemiology and molecular profile of mucosal melanoma: a population-based study in Southern Europe. Cancers. 2022; 14(3): 780.
- 15Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(6): 472-492.
- 16Nagarajan P, Piao J, Ning J, et al. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020; 33(3): 496-513.
- 17Zanoni DK, Patel SG, Shah JP. Changes in the 8th edition of the American Joint Committee on Cancer (AJCC) staging of head and neck cancer: rationale and implications. Curr Oncol Rep. 2019; 21(6): 52.
- 18Cui C, Lian B, Zhang X, et al. An evidence-based staging system for mucosal melanoma: a proposal. Ann Surg Oncol. 2022; 29(8): 5221-5234.
- 19Kottakota V, Warikoo V, Yadav AK, et al. Clinical and oncological outcomes of surgery in Anorectal melanoma in Asian population: a 15 year analysis at a tertiary cancer institute. Cancer Treat Res Commun. 2021; 28:100415.
- 20Temperley HC, O'Sullivan NJ, Keyes A, et al. Optimal surgical management strategy for treatment of primary anorectal malignant melanoma-a systematic review and meta-analysis. Langenbecks Arch Surg. 2022; 407(8): 3193-3200.
- 21Matsuda A, Miyashita M, Matsumoto S, et al. Abdominoperineal resection provides better local control but equivalent overall survival to local excision of anorectal malignant melanoma: a systematic review. Ann Surg. 2015; 261(4): 670-677.
- 22Perez DR, Trakarnsanga A, Shia J, et al. Locoregional lymphadenectomy in the surgical management of anorectal melanoma. Ann Surg Oncol. 2013; 20(7): 2339-2344.
- 23Smith HG, Glen J, Turnbull N, et al. Less is more: a systematic review and meta-analysis of the outcomes of radical versus conservative primary resection in anorectal melanoma. Eur J Cancer. 2020; 135: 113-120.
- 24Ciarrocchi A, Pietroletti R, Carlei F, Amicucci G. Extensive surgery and lymphadenectomy do not improve survival in primary melanoma of the anorectum: results from analysis of a large database (SEER). Colorectal Dis. 2017; 19(2): 158-164.
- 25Fields AC, Goldberg J, Senturk J, et al. Contemporary surgical management and outcomes for anal melanoma: a national cancer database analysis. Ann Surg Oncol. 2018; 25(13): 3883-3888.
- 26Ford MM, Kauffmann RM, Geiger TM, Hopkins MB, Muldoon RL, Hawkins AT. Resection for anal melanoma: is there an optimal approach? Surgery. 2018; 164(3): 466-472.
- 27Taylor JP, Stem M, Yu D, et al. Treatment strategies and survival trends for anorectal melanoma: is it time for a change? World J Surg. 2019; 43(7): 1809-1819.
- 28Zheng Y, Cong C, Su C, Sun Y, Xing L. Epidemiology and survival outcomes of primary gastrointestinal melanoma: a SEER-based population study. Int J Clin Oncol. 2020; 25(11): 1951-1959.
- 29Menon H, Patel RR, Cushman TR, et al. Management and outcomes of primary anorectal melanoma in the United States. Future Oncol. 2020; 16(8): 329-338.
- 30Naqvi J, Lee A, Lederman A, Kavi A, Osborn VW, Schreiber D. Patterns of care and survival outcomes in the treatment of anal melanoma. J Gastrointest Cancer. 2020; 51(1): 211-216.
- 31Mazal S, Najmi M, Ahmad M, et al. Gastrointestinal melanoma: outcomes of surgery and immunotherapy. J Clin Oncol. 2022; 40(16):e16224.
- 32Wang M, Zhang Z, Zhu J, et al. Tumour diameter is a predictor of mesorectal and mesenteric lymph node metastases in anorectal melanoma. Colorectal Dis. 2013; 15(9): 1086-1092.
- 33Kirchoff DD, Deutsch GB, Foshag LJ, Lee JH, Sim MS, Faries MB. Evolving therapeutic strategies in mucosal melanoma have not improved survival over five decades. Am Surg. 2016; 82(1): 1-5.
- 34Ranjith S, Muralee M, Sajeed A, et al. Anorectal melanoma: experience from a tertiary cancer care centre in South India. Ann R Coll Surg Engl. 2018; 100(3): 185-189.
- 35Jutten E, Kruijff S, Francken AB, Van Westreenen HL, Wevers KP. Survival following surgical treatment for anorectal melanoma seems similar for local excision and extensive resection regardless of nodal involvement. Surg Oncol. 2021; 37:101558.
- 36Bleicher J, Cohan JN, Huang LC, et al. Trends in the management of anorectal melanoma: a multi-institutional retrospective study and review of the world literature. World J Gastroenterol. 2021; 27(3): 267-280.
- 37Wong DL, Glazer ES, Tsao M, Deneve JL, Fleming MD, Shibata D. Impact of adjuvant therapies following surgery for anal melanoma. Am J Surg. 2022; 223(6): 1132-1143.
- 38Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20): 1877-1888.
- 39Eggermont AMM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021; 22(5): 643-654.
- 40Weber J, Mandala M, Del Vecchio M, et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N Engl J Med. 2017; 377(19): 1824-1835.
- 41Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017; 376(23): 2211-2222.
- 42Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014; 370(7): 599-609.
- 43Mitra D, Rao PK, Nagarajan P, et al. Outcomes after sphincter-sparing local therapy for anorectal melanoma: 1989 to 2020. Pract Radiat Oncol. 2022; 12(5): 437-445.
- 44Amaria RN, Postow M, Burton EM, et al. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022; 611(7934): 155-160.
- 45Rozeman EA, Menzies AM, Van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019; 20(7): 948-960.
- 46Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023; 388(9): 813-823.
- 47Tchelebi L, Guirguis A, Ashamalla H. Rectal melanoma: epidemiology, prognosis, and role of adjuvant radiation therapy. J Cancer Res Clin Oncol. 2016; 142(12): 2569-2575.
- 48Kelly P, Zagars GK, Cormier JN, Ross MI, Guadagnolo BA. Sphincter-sparing local excision and hypofractionated radiation therapy for anorectal melanoma. Cancer. 2011; 117(20): 4747-4755.
- 49Ballo MT, Gershenwald JE, Zagars GK, et al. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002; 20(23): 4555-4558.
- 50Mitra D, Rao PK, Nagarajan P, et al. 30-year experience managing anorectal melanoma with sphincter-sparing local excision and hypofractionated radiation therapy. Int J Radiat Oncol Biol Phys. 2021; 111(3):e60.
- 51Larkin J, Minor D, D'Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial. J Clin Oncol. 2018; 36(4): 383-390.
- 52Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017; 390(10105): 1853-1862.
- 53Long GV, Hauschild A, Santinami M, et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N Engl J Med. 2017; 377(19): 1813-1823.
- 54Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019; 381(16): 1535-1546.
- 55Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015; 373(1): 23-34.
- 56Weber JS, Schadendorf D, Del Vecchio M, et al. Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915). J Clin Oncol. 2023; 41(3): 517-527.
- 57Hamid O, Robert C, Ribas A, et al. Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006. Br J Cancer. 2018; 119(6): 670-674.
- 58Carvajal RD. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305(22): 2327-2334.
- 59Kottschade LA, Pond GR, Olszanski AJ, et al. SALVO: single arm trial of ipilimumab and nivolumab as adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2023; 29(12): 2220-2225.
- 60Lian B, Si L, Cui C, et al. Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma. Clin Cancer Res. 2013; 19(16): 4488-4498.
- 61Lian B, Si L, Chi ZH, et al. Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial. Ann Oncol. 2022; 33(10): 1061-1070.
